Business
Sun BioPharma Provides Business Update and Files Annual Report for 2018
Sun BioPharma Provides Business Update and Files Annual Report for 2018.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\nFront-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as President and Chief Executive Officer, effective November 1, 2018$2.2M in private financing raised between December 2018 and January 2019 $1.3M in the private sale of convertible notes in December 2018Completed private sale of convertible notes in January 2019 for additional $0.9M MINNEAPOLIS, March 22, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the year ended December 31, 2018.\n Front-Line Combination PDA Study The Company’s clinical team, working in conjunction with its medical advisors and physician investigators, have been enrolling patients in the second cohort in its study, “SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel in Newly Diagnosed Patients with Metastatic Pancreatic Ductal Adenocarcinoma.” The study includes a dose-escalation phase with sequential cohorts of patients receiving treatment at each of three dose levels. The dose-escalation phase is to be followed by an expansion phase at the optimal dose level. Contract research organizations have been engaged to assist in managing the study at one site in the United States (Courante Oncology), the University of Florida where SBP-101 was invented, and at three sites in Australia (Novotech). Dr. Suzanne Gagnon, Chief Medical Officer remarked, “We appreciate the enthusiastic commitment of our current investigators and are now in the process of evaluating additional investigational sites for the expansion phase of the study, which we hope to commence later this year. Expanding in both the US and Australia will allow more patients to have access to SBP-101 while receiving gemcitabine and nab-paclitaxel.” Company Names Founder and Executive Chairman as Chief Executive Officer Effective October 31, 2018, Michael T. Cullen, MD, MBA, the company’s Executive Chairman, has accepted the additional responsibilities of President and CEO of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd. “Pleased with our...